Key data
| Regulation | Commission Implementing Decision (EU) 2026/2124, of 24 September 2026 |
|---|---|
| Publication | 25 September 2026 (EU Official Journal) |
| Entry into force | 24 September 2026 |
| Active substance | IPBC (3-iodo-2-propynyl butylcarbamate) |
| Type of biocidal product | Type 13 — Protection of films, coatings and paints |
| Legal basis | Regulation (EU) No 528/2012 on biocides |
| Affected parties | Manufacturers, importers and distributors of biocides with IPBC for coatings and films |
| Category | European Regulation |
| Year | 2026 |
If your company manufactures, imports or distributes paints, coatings or film protection products containing IPBC, this decision directly affects you. The European Commission has avoided a regulatory vacuum that would have forced products to be withdrawn from the market or reformulated hastily.
Commission Implementing Decision (EU) 2026/2124, adopted on 24 September 2026 under the Regulation (EU) No 528/2012 on biocides, delays the expiry date of IPBC approval for biocides of product type 13. The reason: the evaluation process could not be completed before the original expiry date.
What does this regulation establish?
IPBC (3-iodo-2-propynyl butylcarbamate) is an active substance widely used as a fungicide and inhibitor of microbial growth in paints, varnishes and coatings. Its approval as a biocide of product type 13 —a specific category for the protection of films and coatings— was subject to an expiry date which, had it not been extended, would have created an illegal situation for products containing it.
The extension mechanism is expressly provided for in Regulation (EU) No 528/2012: when the technical evaluation of an active substance cannot be concluded before its current approval expires, the Commission may delay that expiry date to avoid unnecessary harm to operators and the market.
| Element | Detail |
|---|---|
| Active substance affected | IPBC — 3-iodo-2-propynyl butylcarbamate |
| Biocide category | Product type 13: protection of films, coatings and paints |
| Immediate effect | Approval remains valid beyond the original expiry date |
| Reason for extension | The evaluation process could not be completed before the original expiry date |
| Pending outcome | The evaluation will determine whether approval is renewed, modified or definitively denied |
Economic and operational impact
The most immediate impact of this decision is positive in the short term: companies avoid costs of urgent reformulation, product withdrawal from the market and possible loss of market share.
Without the extension, companies would have had to face:
- Withdrawal of IPBC-containing products from the European market before completing the evaluation.
- Accelerated reformulation of products to replace IPBC with another approved active substance.
- Costs of re-authorization and re-labeling of the entire affected range.
- Possible loss of contracts with customers requiring continuous regulatory compliance.
The real operational risk is transferred to the future: when the evaluation concludes, the outcome may be renewal of approval (unchanged), renewal with new conditions (for example, use restrictions or maximum concentrations) or definitive denial. In the latter case, companies will have to reformulate or withdraw products, but will have sufficient time to plan it.
Who does it affect?
- Manufacturers of paints, varnishes and coatings that use IPBC as a preservative or fungicide in their formulations.
- Manufacturers of biocides of product type 13 registered under Regulation (EU) No 528/2012.
- Importers of biocidal products with IPBC intended for the protection of films and coatings in the European market.
- Distributors and marketers of these products in Spain and the rest of the EU.
- Compliance and regulatory officers in chemical and coatings companies.
- Regulatory advisors and consultants who manage biocide authorizations for their clients.
Practical example
A Spanish company manufacturing waterproofing paints for facades uses IPBC as a fungicide in several references in its catalog, all registered as biocides of product type 13.
Without this extension, upon reaching the original expiry date of IPBC approval, the company would have had to withdraw those references from the market or reformulate them urgently —with the costs of development, testing, re-registration and re-labeling that this entails— without guarantee of being able to maintain the same technical performance of the product.
Thanks to Commission Implementing Decision (EU) 2026/2124, that company can continue manufacturing and marketing its products without any interruption. What it must do is monitor the final outcome of the IPBC evaluation: if approval is renewed with new conditions (for example, a maximum permitted concentration lower than the current one), it will have to adapt its formulations within the timeframe established by the new decision.
What should companies do now?
- Verify whether your products contain IPBC as an active substance in the category of biocides of product type 13 (protection of films, coatings and paints). If so, this regulation directly affects you.
- Confirm that your product authorizations are valid under Regulation (EU) No 528/2012 and that they correctly reflect the extension of IPBC approval.
- Establish a monitoring alert on the ongoing IPBC evaluation. The final outcome —renewal, modification or denial— will determine the actions you will need to take and the timeframe.
- Prepare a contingency reformulation plan in case the evaluation concludes with a denial or with more restrictive conditions. Having it ready in advance avoids emergency costs.
- Inform your supply chain (distributors, industrial customers) that products with IPBC maintain their regulatory compliance, avoiding order cancellations due to regulatory uncertainty.
- Check the status of the evaluation in the ECHA register of biocidal active substances to stay informed of the progress of the process.
Frequently asked questions
What is IPBC and what is it used for in type 13 biocides?
IPBC (3-iodo-2-propynyl butylcarbamate) is an active fungicidal substance used in biocides of product type 13, which corresponds to products for the protection of films, coatings and paints. Its function is to inhibit the growth of fungi and microorganisms that deteriorate these surfaces.
Can I continue selling products with IPBC after this decision?
Yes. Commission Implementing Decision (EU) 2026/2124 expressly extends the approval of IPBC for biocides of product type 13, which allows manufacturers, importers and distributors to continue marketing their products without interruption or need for immediate reformulation.
When will it be known if IPBC approval is definitively renewed?
The decision does not establish a specific date for the conclusion of the evaluation. Operators must monitor the process through the ECHA and the EU Official Journal. The outcome may be renewal of approval, renewal with new conditions or definitive denial.
What happens if the IPBC evaluation concludes with a denial?
If the evaluation concludes with a definitive denial of approval, companies will have to withdraw biocidal products with IPBC of type 13 from the market or reformulate them by replacing this active substance. The new decision that establishes this will include an adaptation period. This is why it is advisable to have a contingency reformulation plan ready in advance.
What regulation governs the approval of biocides such as IPBC in the EU?
The approval of biocidal active substances in the European Union is governed by Regulation (EU) No 528/2012 of the European Parliament and of the Council. This regulation expressly provides for the extension mechanism used in this decision when the evaluation cannot be completed before the original expiry date.
Official source
View complete regulation in official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602124
